REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

The goal of this study is to evaluate the recovery of erectile function at six months after hormonal therapy cessation in male patients affected by advanced prostate cancer and undergoing radiotherapy. The main questions are: * How well and how quickly do patients recover their sexual function and overall quality of life after stopping hormone therapy and receiving radiotherapy? * How do the details of the radiation treatment (like the dose and how it's delivered) relate to treatment success, side effects, and long-term outcomes such as cancer control, survival, and financial impact? Participants will receive hormonal therapy (Relugolix) following by radiotherapy. They will complete questionnaires on sexual function, quality of life, and financial impact before, during and after treatment, and attend follow-up visits for health assessments. The study will measure how many patients recover erectile function within six months of stopping hormonal therapy, how long recovery takes, how treatment doses relate to outcomes, and assess cancer control, side effects, quality of life, and survival.

NCT Number	NCT07302451
Lead Sponsor	National Cancer Institute, Naples
Conditions	Prostate Cancer (Adenocarcinoma)
Enrollment	50 participants
Start Date	2026-02-23
Primary Completion	2027-05-31 (estimated)
Study Completion	2031-02-23 (estimated)
Updated on ClinicalTrials.gov	2026-07-21